 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

StockNews.com initiated coverage on shares of MediciNova (NASDAQ:MNOV - Free Report) in a report published on Friday morning. The brokerage issued a hold rating on the biopharmaceutical company's...

MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com

LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

LA JOLLA, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

LA JOLLA, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society

StockNews.com started coverage on shares of MediciNova (NASDAQ:MNOV  Free Report) in a report released on Tuesday. The brokerage issued a hold rating on the biopharmaceutical companys...

StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV)

StockNews.com started coverage on shares of MediciNova (NASDAQ:MNOV  Free Report) in a research report released on Tuesday. The firm issued a hold rating on the biopharmaceutical...

MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

MediciNova's MN-166 shows efficacy in lung injury study

LA JOLLA, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology

StockNews.com assumed coverage on shares of MediciNova (NASDAQ:MNOV  Free Report) in a research report report published on Saturday morning. The brokerage issued a hold rating on the...

Equities research analysts at StockNews.com started coverage on shares of MediciNova (NASDAQ:MNOV  Get Free Report) in a report issued on Tuesday. The firm set a hold rating on...

StockNews.com Initiates Coverage on MediciNova (NASDAQ:MNOV)

MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. The company was founded by Yuichi Iwaki on September 26, 2000, and is headquartered in La Jolla, CA.

Volume (M)	21,358.00
52-Wk High	$2.66
52-Wk Low	$1.26

MNOV Medicinova Inc

About

Feed

News

Sentiment

Earnings

Fundamentals